Results 101 to 110 of about 1,373,329 (318)

Chemotherapy of small cell lung cancer [PDF]

Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer, and chemotherapy plays a central role in its treatment. In recent years, there have been major advances in the treatment landscape for small cell lung cancer, notably the advent of
Yeh, Chiachen
core  

Preoperative elevation of serum C-reactive protein as an indicator of poor prognosis for early-stage esophageal squamous cell carcinoma

Kaohsiung Journal of Medical Sciences, 2013
Preoperative elevation of serum C-reactive protein (CRP) is reportedly associated with poor prognosis in several types of cancer. This study investigated the role of serum CRP as a prognostic factor in early-stage esophageal squamous cell carcinoma (ESCC)
Zheng-Bo Song, Bao-Chai Lin, Bo Li, Chun-Xiao He, Bei-Bei Zhang, Lan Shao, Yi-Ping Zhang   +6 more
doaj   +1 more source

Solid Pseudopapillary Neoplasm of the Pancreas in Children and Adolescents: Expert Recommendations

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Solid pseudopapillary neoplasm of the pancreas (SPN) is a rare low‐grade malignant exocrine pancreatic tumor, mostly discovered during the second decade of life in females, with a very good prognosis, provided microscopically complete surgical excision is achieved.
Sabine Irtan, Michael Abele, Calogero Virgone, Michaela Kuhlen, Ricardo Lopez‐Almarez, Tal Ben‐Ami, Ewa Bien, Maja Cesen, Malgorzata A. Krawczyk, Andrea Ferrari, Gianni Bisogno, Yves Reguerre, Dominik T. Schneider, Louise Galmiche, Jorg Fuchs, Sarah Braungart, Bilgehan Yalcin, Ines B. Brecht, Daniel Orbach   +18 more
wiley   +1 more source

The current role of fluoropyrimidines in cancer chemotherapy [PDF]

, 2018
The main aim of chemotherapy has always been to destroy tumor cells without necessarily affecting the normal cells, hence the need for more directly acting drugs.
Ezeibekwe, Nancy Chinonyerem
core  

Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia - a randomised SAL pilot study [PDF]

, 2012
INTRODUCTION: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML.
Ulrich Dührsen, Anja Koschmieder (106749), Matthias Stelljes, Christian Thiede (106768), Carsten Müller-Tidow, Nicola Tidow (106758), Noppeney, Richard, Utz Krug, Gerhard Ehninger, Daniela Schwammbach (106754), Steffen Koschmieder, Nicola Tidow, Wolfgang E Berdel, Markus Schaich (106764), Stelljes, Matthias, Matthias Stelljes (106772), Utz Krug (106744), Carsten Müller-Tidow (105305), Krug, Utz, Tidow, Nicola, Bug, Gesine, Schaich, Markus, Björn Steffen, Richard Noppeney (106769), Gerss, Joachim, Christian Thiede, Joachim Gerss, Schwammbach, Daniela, Thomas Büchner, Björn Steffen (106759), Büchner, Thomas, Ulrich Dührsen (106782), Anja Koschmieder, Christoph Röllig, Steffen, Björn, Markus Schaich, Steffen Koschmieder (106779), Thomas Büchner (106775), Hubert Serve, Koschmieder, Steffen, Christian H. Brandts (106762), Ehninger, Gerhard, Brandts, Christian Hubertus, Berdel, Wolfgang E., Joachim Gerss (106757), Gerhard Ehninger (106788), Dührsen, Ulrich, Wolfgang E. Berdel (106792), Richard Noppeney, Gesine Bug (106760), Serve, Hubert, Müller-Tidow, Carsten, Daniela Schwammbach, Christian H Brandts, Hubert Serve (106786), Thiede, Christian, Gesine Bug, Koschmieder, Anja, Röllig, Christoph, Christoph Röllig (106766)   +59 more
core   +1 more source

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer

Thoracic Cancer, 2020
Background Anaplastic lymphoma kinase (ALK) fusion genes are found in 3%–5% of non‐small cell lung cancers (NSCLCs). ALK inhibitors show a very high response rate to ALK‐positive NSCLCs. However, the emergence of acquired resistance is inevitable.
Ken Takahashi, Yosuke Seto, Koutaroh Okada, Shinya Uematsu, Ken Uchibori, Mika Tsukahara, Tomoko Oh‐hara, Naoya Fujita, Noriko Yanagitani, Makoto Nishio, Kenichi Okubo, Ryohei Katayama   +11 more
doaj   +1 more source

Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A‐Rearranged ALL

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Adding blinatumomab to standard chemotherapy for infants with KMT2A‐rearranged acute B‐cell lymphoblastic leukemia (KMT2A‐r B‐ALL) improves outcomes. Although blinatumomab impairs immunoglobulin G (lgG) production, increasing infection susceptibility, IgG recovery remains poorly understood.
Miguel Vieira Martins, Paola de Lorenzo, Rishi S. Kotecha, Andishe Attarbaschi, Gabriele Escherich, Karsten Nysom, Jan Stary, Alina Ferster, Benoit Brethon, Franco Locatelli, Martin Schrappe, Peggy E. Scholte‐van Houtem, Maria G. Valsecchi, Rob Pieters, Inge M. van der Sluis   +14 more
wiley   +1 more source

Bridging the Gap in Neuroblastoma Care: Consensus‐Based Statements With Recommendations for Improved Patient and Caregiver Experiences

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Neuroblastoma's complex, heterogeneous biology poses significant diagnostic and therapeutic challenges, often requiring caregivers to absorb complex information and participate in time‐sensitive decisions. However, caregivers often feel unprepared to evaluate options.
Vickie Buenger, Joseph Bauer, Jennifer Diamond, Maggie Fader, Shae Hansen, Jacqueline M. Kraveka, Johanna Schoen, Amber Shearer, Dena Sherwood   +8 more
wiley   +1 more source

Cisplatin, Etoposide, and Vincristine Combination Chemotherapy in the Treatment of Non-Small Cell Lung Cancer [PDF]

, 1993
1993-03Thirty patients with previously untreated, inoperable non-small cell lung cancer (NSCLC) were treated with cisplatin, etoposide and vincristine.
NAGURA, EIICHI, SHIMOKATA, KAORU, SAITO, HIROSHI, WATANABE, ATSUSHI, ICHIYAMA, SATOSHI, NOMURA, FUMIO, SAKAI, SHUZO, SAKA, HIDEO, SAITO, HIDEHIKO   +8 more
core   +1 more source

A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer

npj Precision Oncology
Brigatinib-based therapy was effective against osimertinib-resistant EGFR C797S mutants and is undergoing clinical studies. However, tumor relapse suggests additional resistance mutations might emerge.
Mai Suzuki, Ken Uchibori, Tomoko Oh-hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto-Niino, Yusuke Kawase, Mikako Shirouzu, Yasushi Okuno, Makoto Nishio, Naoya Fujita, Ryohei Katayama   +15 more
doaj   +1 more source